The clinical relevance of ABO blood type in 100 patients with acute subdural hematoma

PLoS One. 2018 Oct 4;13(10):e0204331. doi: 10.1371/journal.pone.0204331. eCollection 2018.

Abstract

Objective: The correlation of depleted blood through midline shift in acute subdural hematoma remains the most reliable clinical predictor to date. On the other hand, patient's ABO blood type has a profound impact on coagulation and hemostasis. We conducted this study to evaluate the role of patient's blood type in terms of incidence, clinical course and outcome after acute subdural hematoma bleeding.

Methods: 100 patients with acute subdural hematoma treated between 2010 and 2015 at the author's institution were included. Baseline characteristics and clinical findings including Glasgow coma scale, Glasgow outcome scale, hematoma volume, rebleeding, midline shift, postoperative seizures and the presence of anticoagulation were analyzed for their association with ABO blood type.

Results: Patient's with blood type O were found to have a lower midline shift (p<0.01) and significantly less seizures (OR: 0.43; p<0.05) compared to non-O patients. Furthermore, patients with blood type A had the a significantly higher midline shift (p<0.05) and a significantly increased risk for postoperative seizures (OR: 4.01; p<0.001). There was no difference in ABO blood type distribution between acute subdural hematoma patients and the average population.

Conclusion: The ABO blood type has significant influence on acute subdural hematoma sequelae. Patient's with blood type O benefit in their clinical course after acute subdural hematoma whereas blood type A patients are at highest risk for increased midline shift and postoperative seizures. Further studies elucidating the biological mechanisms of blood type depended hemostaseology and its role in acute subdural hematoma are required for the development of an appropriate intervention.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Grouping and Crossmatching
  • Disease Progression
  • Female
  • Glasgow Coma Scale
  • Glasgow Outcome Scale
  • Hematoma, Subdural, Acute / blood*
  • Hematoma, Subdural, Acute / epidemiology
  • Hematoma, Subdural, Acute / surgery
  • Humans
  • Incidence
  • Male
  • Nootropic Agents / therapeutic use
  • Postoperative Complications / blood
  • Postoperative Complications / epidemiology
  • Prevalence
  • Recurrence
  • Retrospective Studies
  • Risk Factors
  • Seizures / blood
  • Seizures / epidemiology
  • Treatment Outcome

Substances

  • Nootropic Agents

Grant support

Dr. Daniel Dubinski is a Else Kröner-Fresenius-Foundation scholar.